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Abstract
© 2017 Kh. S. Khaertynov et al. Neonatal sepsis is a significant health issue associated with
high mortality. Immune responses associated with neonatal sepsis, such as proinflammatory
cytokine production, are believed to play a central role in the pathogenesis of this disease. In
the present study, serum levels of the proinflammatory cytokines TNF-α, IL1-β, and IL-6 and the
anti-inflammatory cytokines IL-4 and IL-10 were evaluated for 25 subjects with neonatal sepsis.
We observed that subjects with late onset of sepsis (LOS), as well as those with early onset of
sepsis (EOS), had a substantial increase in serum TNF-α. In contrast to EOS, subjects with LOS
demonstrated a significant increase in serum levels IL-6 and IL-10. Additionally, we observed a
significant difference in cytokine profiles between acute and postacute cases of neonatal sepsis.
For instance, the level of proinflammatory cytokines, such as TNF-α and IL-6, was elevated in
the acute phase, whereas the production of anti-inflammatory cytokines, such as IL-10, became
substantially upregulated during the postacute phase. Additionally, no correlation was observed
between cytokine levels and CRP levels or lymphocyte counts. Thus, in contrast to CRP levels
and lymphocyte counts, examination of the cytokine profile can provide valuable information
when determining the most effective therapy for treating neonatal sepsis. This information may
be useful to physicians when determining if anti-inflammatory or immune stimulatory therapy is
warranted.
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